-37%

est. 2Y upside i

HealthcareSeries B

Rank

#437

Sector

Healthtech, Women's Health

Est. Liquidity

~4Y

Data Quality

Data: Medium

Allara presents a strong equity opportunity for a job seeker, driven by its exceptional 300% YoY revenue growth in 2024 and its focus on a large, underserved women's hormonal health market.

Last updated: March 10, 2026

Bull (35%)+250%

Allara maintains its hyper-growth trajectory by successfully expanding its condition coverage beyond PCOS to include a broader range of women's hormonal conditions like fertility and menopause support, and further deepening its insurance partnerships. This market leadership and continued rapid expansion drive revenue significantly higher, justifying a valuation of over $500M (3.5x current valuation) by 2027.

Base (45%)+100%

Allara continues its strong growth, solidifying its position in the specialized women's hormonal health market and expanding its patient base across all 50 states. While facing increased competition from both niche players and larger digital health platforms, Allara's integrated care model and established partnerships allow it to double its valuation to $290M (2x current valuation) by 2027.

Bear (20%)-60%

Growth slows significantly due to intensified competition from well-funded incumbents like Maven expanding aggressively into specialized hormonal care, or unforeseen regulatory hurdles. This leads to a flat or down round, resulting in a valuation of $58M (a 60% decrease), which, given the $38.5M in liquidation preferences, would wipe out most common stock value for employees.

Est. time to liquidity~3.5 years

Preference Stack Risk

high

Funding Intensity

27%

Investors hold $38.5M in liquidation preferences. In an exit at or below the current $145M valuation, common stock holders would be behind these preferences, potentially receiving little or nothing.

Dilution Risk

moderate

As a Series B company, Allara will likely require 1-2 more significant funding rounds before a liquidity event, which will lead to further dilution for existing equity holders.

Secondary Liquidity

limited

There is no explicit information about active secondary markets or tender offers for Allara's shares, suggesting limited liquidity for employee equity at this stage.

Questions to Ask at the Interview

Strategic questions based on Allara's data — designed to show you've done your homework.

  • 1

    “How is Allara planning to defend and expand its market share against larger digital health incumbents like Maven, especially given their recent significant funding rounds?”

  • 2

    “With the successful expansion to all 50 states and positive clinical outcomes, what are the key strategic priorities for Allara over the next 18-24 months to maintain its hyper-growth trajectory?”

  • 3

    “Given the Series B funding, what is the anticipated timeline and strategy for a liquidity event for employees, and how does the company plan to manage potential dilution in future funding rounds?”

Community

Valuation Sentiment

Our model estimates -37% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.